Sigma-Aldrich Corporation's Sigma Life Science Business to Distribute Worldwide Olink Bioscience's Protein Interaction Analysis

    Sigma-Aldrich Corporation's Sigma Life Science Business to Distribute
     Worldwide Olink Bioscience's Protein Interaction Analysis Technology

Complements Sigma Life Science's Antibody, RNAi, and Gene Editing Technologies

PR Newswire

ST. LOUIS, Feb. 12, 2013

ST. LOUIS, Feb. 12, 2013 /PRNewswire/ -- Sigma-Aldrich^® Corporation (NASDAQ:
SIAL), a leading Life Science and High Technology Company, announced that
Sigma^® Life Science, its innovative biological products and services
business, signed an agreement to distribute worldwide Olink Bioscience's
Duolink^® In Situ products, which present a new disruptive method for imaging
and measuring protein-protein interactions in unmodified cells. The Duolink In
Situ products work in tandem with Sigma Life Science's broad antibody
portfolio and will allow researchers to target the precise protein of interest
and enable robust analyses and imaging. For more information, visit

The versatile technology, among other applications, can be used in combination
with CompoZr^® Zinc Finger Nuclease-mediated gene editing to track knocked-out
or knocked-in genes and with MISSION^® RNA interference technologies to track
protein expression following gene knockdown. "The synergy between Olink and
Sigma Life Science's global support network will help the scientific community
to access and to accelerate the adoption of the powerful Duolink technology,"
said Josef Zihlmann, Vice President at Sigma Life Science.

The proprietary PLA^® technology allows Olink's Duolink In Situ products to
quickly image the locations of single protein-protein interactions regardless
of strength, measure protein expression levels, and identify relative changes
in post-translational modification events. The technique relies upon two
target-specific primary antibodies, a "plus" and "minus" pair of
species-specific PLA probes conjugated to DNA oligos that—when a target pair
of proteins are in close proximity—can hybridize to trigger a rolling circle
amplification reaction. Fluorescent detection probes bind the several
hundred-fold amplified DNA at high density, allowing visualization of single
protein–protein interactions inside an intact cell using a standard
fluorescence microscope.

"The ability to visualize these protein-protein interactions in unmodified
cells under endogenous expression and at very low levels is a fundamental
advance that allows greater insight into basic biology,pathways, spatial
phenomena and potential therapeutic targets in those pathways," said Zihlmann.

More than 350 publications in the past six years have relied upon the Duolink
method, which is featured in an average of five publications per week by
academic and pharmaceutical researchers. The Sigma Life Science Prestige^®
antibody collection complements the technology with its portfolio of more than
14,000 antibodies that have been validated by immunohistochemistry, a key
requirement for Duolink In Situ products to target specific proteins of

"We believe the agreement with Sigma Life Science will build awareness and
develop the market for Duolink In Situ through their global sales and support
organization serving our growing customer base locally," said Simon
Fredriksson, CEO and President of Olink Bioscience. "Sigma Life Science's
extensive product range for cell biology is a perfect context for customers
interested in Duolink In Situ."

For more information, visit

Cautionary Statement: The foregoing release contains forward-looking
statements that can be identified by terminology such as "disruptive,"
"robust," "fundamental advance," "greater insight" or similar expressions, or
by expressed or implied discussions regarding potential future revenues from
products derived there from. You should not place undue reliance on these
statements. Such forward-looking statements reflect the current views of
management regarding future events, and involve known and unknown risks,
uncertainties and other factors that may cause actual results to be materially
different from any future results, performance or achievements expressed or
implied by such statements. There can be no guarantee that Olink's technology
or related Sigma technologies and services will assist the Company to achieve
any particular levels of revenue in the future. In particular, management's
expectations regarding products associated with Olink's technology or related
Sigma technologies and services could be affected by, among other things,
unexpected regulatory actions or delays or government regulation generally;
the Company's ability to obtain or maintain patent or other proprietary
intellectual property protection; competition in general; government, industry
and general public pricing pressures; the impact that the foregoing factors
could have on the values attributed to the Company's assets and liabilities as
recorded in its consolidated balance sheet, and other risks and factors
referred to in Sigma-Aldrich's current Form 10-K on file with the US
Securities and Exchange Commission. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those anticipated, believed, estimated
or expected. Sigma-Aldrich is providing the information in this press release
as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new
information, future events or otherwise.

About Sigma-Aldrich: Sigma-Aldrich Corporation is a leading Life Science and
High Technology company whose biochemical, organic chemical products, kits and
services are used in scientific research, including genomic and proteomic
research, biotechnology, pharmaceutical development, the diagnosis of disease
and as key components in pharmaceutical, diagnostics and high technology
manufacturing. Sigma-Aldrich customers include more than 1.3 million
scientists and technologists in life science companies, university and
government institutions, hospitals and industry. The Company operates in 38
countries and has nearly 9,000 employees whose objective is to provide
excellent service worldwide. Sigma-Aldrich is committed to accelerating
customer success through innovation and leadership in Life Science and High
Technology. For more information about Sigma-Aldrich, please visit its website

About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich business that
represents the Company's leadership in innovative biological products and
services for the global life science market and offers an array of
biologically-rich products and reagents that researchers use in scientific
investigation. Product areas include biomolecules, genomics and functional
genomics, cells and cell-based assays, transgenics, protein assays, stem cell
research, epigenetics and custom services/oligonucleotides. Sigma Life Science
also provides an extensive range ofcritical bioessentials like biochemicals,
antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and
histology, nucleotides, amino acids and their derivatives, and cell culture

Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Co, LLC registered in
the US and other countries. CompoZr, MISSION and Prestige are registered
trademarks of Sigma-Aldrich Co. LLC. Duolink and PLA are registered trademarks
of Olink AB.

SOURCE Sigma-Aldrich Corporation

Contact: Sigma-Aldrich, Lindsay Poepsel, +1-314-286-7751,; or Media Inquiries, Harris D. McKinney, Inc, Alan
Zachary, Ph.D., +1-312-506-5220,, or Ryan
Ferrell, +1-312-506-5202,
Press spacebar to pause and continue. Press esc to stop.